Literature DB >> 19398878

Renal cell carcinoma: biological features and rationale for molecular-targeted therapy.

Mototsugu Oya1.   

Abstract

Cancer cells are characterized by indefinite proliferation, invasiveness and metastases. These characteristics are usually related to one another. Namely, cancer cells that proliferate rapidly tend to invade and metastasize. Renal cell carcinoma (RCC) typically does not proliferate rapidly nor does it invade the surrounding tissues, but it does metastasize. RCC has several peculiar characteristics that are not observed in other cancers: a relatively late recurrence, a high frequency of paraneoplastic syndrome, hypervascularity and the spontaneous regression of metastatic lesions after the excision of the primary tumor. These clinical observations suggest that cytokines or growth factors are important contributors to microenvironments favoring the growth of cancer cells. Thus, the blockade of cell-to-cell communication might have some therapeutic potential. Accordingly, a popular strategy for molecular-targeted therapy for RCC targets the vasculization of RCC induced by vascular endothelial growth factor (VEGF). This review highlights the biological features of RCC that are relevant to molecular-targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398878     DOI: 10.2302/kjm.58.1

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  7 in total

Review 1.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

2.  Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.

Authors:  Chao Xie; Edward M Schwarz; Erik R Sampson; Robinder S Dhillon; Dan Li; Regis J O'Keefe; Wakenda Tyler
Journal:  J Orthop Res       Date:  2011-08-01       Impact factor: 3.494

3.  Molecular aspects of renal cell carcinoma: a review.

Authors:  Hari Koul; Jung-Sik Huh; Kyle O Rove; Luiza Crompton; Sweaty Koul; Randall B Meacham; Fernando J Kim
Journal:  Am J Cancer Res       Date:  2010-12-18       Impact factor: 6.166

Review 4.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

5.  Type 2 diabetes and the risk of renal cell cancer in women.

Authors:  Hee-Kyung Joh; Walter C Willett; Eunyoung Cho
Journal:  Diabetes Care       Date:  2011-05-20       Impact factor: 19.112

6.  Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Authors:  Francesca Pretto; Carmen Ghilardi; Michele Moschetta; Andrea Bassi; Alessandra Rovida; Valentina Scarlato; Laura Talamini; Fabio Fiordaliso; Cinzia Bisighini; Giovanna Damia; Maria Rosa Bani; Rosanna Piccirillo; Raffaella Giavazzi
Journal:  Oncotarget       Date:  2015-02-20

7.  Impact of body mass index on clinicopathological outcomes in patients with renal cell carcinoma without anorexia-cachexia syndrome.

Authors:  Daisuke Watanabe; Akio Horiguchi; Shinsuke Tasaki; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Keiichi Ito; Tomohiko Asano
Journal:  Mol Clin Oncol       Date:  2017-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.